Trevi Therapeutics' Upcoming Oral Presentation at ERS Congress
Professor Jacky Smith is set to present research that explores the relationship between objective cough counts and improvements in patient-reported outcomes, specifically focusing on nalbuphine ER for patients with idiopathic pulmonary fibrosis (IPF).
Overview of the CANAL Trial Presentation
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a biopharmaceutical company currently in the clinical stage, will share important findings from the Phase 2a CANAL trial at the European Respiratory Society (ERS) Congress. This year's event will take place from September 7-11 in Vienna, Austria, with the presentation scheduled for September 8.
Details About the Congress
The ERS Congress this year aims to unite experts in respiratory medicine to exchange knowledge and discuss advancements. Among the various sessions, there will be a poster presentation dedicated to research studies on chronic cough.
Significance of the Data Presented
During his presentation, Professor Smith will elaborate on how changes in cough frequency are linked to improvements in the quality of life for patients taking nalbuphine ER. Patient-reported outcomes are crucial in clinical trials as they reflect patients' experiences beyond standard clinical measurements. With a significant need for effective treatments for chronic cough in IPF, the insights from this trial aim to fill that gap.
Background on Trevi Therapeutics, Inc.
Trevi Therapeutics is leading the development of the investigational therapy Haduvio™ (oral nalbuphine ER), which is designed to treat chronic cough associated with IPF and refractory chronic cough (RCC). Haduvio acts as an extended-release medication that works both centrally in the brain and peripherally in the lungs, showing potential in providing a comprehensive approach to alleviating chronic cough symptoms.
Impact of Chronic Cough
The effects of chronic cough on patients can be extensive, often resulting in a diminished quality of life across social, physical, and psychological aspects. In the case of IPF, chronic cough can worsen the condition, increasing the risk of disease progression and negative outcomes. Despite the high prevalence of chronic cough among adults and its significant impact, there are currently no approved therapies specifically targeting this issue.
Future Prospects for Haduvio
As Trevi works towards finalizing Haduvio as the official trade name for oral nalbuphine ER, it is essential to understand that the drug's safety and efficacy are still under evaluation by regulatory authorities. The company's initiatives underscore the urgent need for developing treatments in areas with substantial unmet medical needs.
Frequently Asked Questions
What is the focus of Trevi Therapeutics' research?
Trevi Therapeutics is dedicated to developing therapies, particularly Haduvio™, aimed at addressing chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.
When will the data from the CANAL trial be presented?
The findings from the CANAL trial will be presented on September 8 at the European Respiratory Society Congress.
Who is presenting the CANAL trial data?
The presentation will be delivered by Professor Jacky Smith, a respected expert in the field.
Why are patient-reported outcomes significant?
Patient-reported outcomes offer valuable insights into how treatments impact patients' lives, serving as an essential feedback mechanism during clinical trials.
How does Haduvio work in treating chronic cough?
Haduvio functions as an extended-release formulation that acts as a dual-opioid receptor agonist and µ-opioid receptor antagonist, targeting cough mechanisms in both the central nervous system and the lungs.
